

Press Release

Media contact

Emanuela Cariolagian
T +1 213 706 0051
Emanuela.cariolagian1@freseniusmedicalcare.com

Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Contact for analysts and investors

Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com

www.freseniusmedicalcare.com

Fresenius Medical Care Expands Production of *bi*bag® Dry Bicarbonate Concentrate Bags for Hemodialysis in the State of São Paulo in Brazil

- Approximately 154,000 patients undergoing dialysis treatment in Brazil and patients in other Latin American countries will benefit from this advanced technology.
- *bi*bags® are a sustainable and safe solution in comparison to classic liquid bicarbonate canisters.

Bad Homburg (March 28, 2025) – Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, expands production of *bi*bag® dry bicarbonate concentrate bags for hemodialysis in its Jaguariúna factory, in the state of São Paulo, Brazil.

Fresenius Medical Care started the new production of *bi*bag® in March of 2025. The FME plant, located in the city of Jaguariúna, now produces *bi*bag® in a high-level automated production line for the domestic market in Brazil, as well as for export to various Latin American countries.

“This expansion positions Brazil to become one of the few countries in the world to obtain this advanced *bi*bag® production technology,” said Alexandre Franco, country manager of Fresenius Medical Care Brazil. “The company’s major investment leverages state-of-the-art technology that elevates Brazil to emerge self-sufficient in *bi*bag® production,” said Franco.

Innovated by FME, *biBag*[®], a dry concentrate of sodium bicarbonate, is a fundamental product for hemodialysis used in the treatment of chronic kidney disease (CKD) patients.

“This expansion involves the sharing of advanced technology, positioning the Jaguariúna plant as a significant manufacturer of this product line” said Luiz Parente, Fresenius Medical Care’s Plant Director. The country’s autonomy in supplying raw materials needed for *biBag*[®] was a key factor to making this project feasible.”

biBag[®] is used in hemodialysis, a medical treatment that removes excess fluids, and toxins from the blood when the kidneys are no longer able to perform this function effectively. They provide a lightweight and streamlined alternative in comparison to liquid bicarbonate canisters, allowing more protection since it dissolves directly in the machine, while reducing the risk of contamination. This technology is more sustainable than other types of solutions used in hemodialysis therapy, because it takes up less storage space, reduces transportation costs and avoids the use of big plastic canisters.

About Fresenius Medical Care:

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company’s website at www.freseniusmedicalcare.com.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.